◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

ホーム全銘柄 › STE · English version

STERIS plc (STE)

公式財務諸表に基づく売上高、利益、キャッシュフローの推移。

Health Care · ウォール街(米国) · 最終更新: 2026-08-16

STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences.

主要指標

インタラクティブチャートと全財務諸表を見る → バリュエーションモデル(DCF)→

年次損益計算書

損益計算書TTM → 2026-06-302026-03-312025-03-312024-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-312013-03-312012-03-312011-03-312010-03-312009-03-312008-03-312007-03-31
売上高合計$6.0B$5.9B$5.5B$5.1B$4.5B$4.2B$3.1B$3.0B$2.8B$2.6B$2.6B$2.2B$1.9B$1.6B$1.5B$1.4B$1.2B$1.3B$1.3B$1.3B$1.2B
売上総利益$2.7B$2.6B$2.4B$2.2B$2.0B$1.9B$1.3B$1.3B$1.2B$1.1B$1.0B$895M$774M$650M$621M$568M$446M$539M$527M$524M$505M
売上総利益率 %44.4%44.2%44.0%43.2%43.7%44.6%43.2%43.5%42.2%41.7%39.3%40.0%41.9%40.0%41.4%40.4%37.0%42.9%40.6%41.4%42.2%
営業利益(EBIT)$1.1B$1.1B$867M$836M$791M$478M$548M$537M$411M$400M$226M$213M$227M$207M$243M$222M$85M$204M$175M$124M$138M
営業利益率 %18.9%18.6%15.9%16.3%17.4%11.3%17.6%17.7%14.8%15.3%8.7%9.5%12.3%12.8%16.2%15.8%7.1%16.2%13.5%9.8%11.5%
当期純利益$805M$785M$615M$378M$107M$244M$397M$408M$304M$291M$110M$111M$135M$129M$160M$136M$51M$128M$111M$77M$82M
純利益率 %13.3%13.2%11.3%7.4%2.4%5.8%12.8%13.5%10.9%11.1%4.2%5.0%7.3%8.0%10.7%9.7%4.2%10.2%8.5%6.1%6.9%
EBITDA$1.6B$1.4B$1.4B$1.2B$1.0B$774M$736M$640M$584M$417M$358M$320M$283M$312M$286M$140M$261M$236M$202M$205M
1株当たり利益(EPS)$8.17$7.95$6.20$3.81$1.07$2.48$4.63$4.76$3.56$3.39$1.28$1.56$2.25$2.17$2.72$2.31$0.85$2.16$1.86$1.20$1.25
発行済株式数(百万株)99M99M99M100M98M86M86M85M86M86M71M60M60M59M59M60M59M59M64M66M

出典: 企業の公開資料(SEC)。数値をご利用の前に SEC EDGAR でご確認ください。

貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は STE のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/STE

類似企業

本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。

English version →全銘柄

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.